Enveric Biosciences is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Co.'s pipeline of product candidates and ongoing development programs include: EV104 (Cannabidiol and Celecoxib Conjugate), which is used as the targeted indication of Osteoarthritis; EVM-201, which is used as the targeted indication of anxiety; EVM-301, which is used as the targeted indications of mental health indication; Cannabinoid-Infused Topical Product, which is used as the targeted indication of oncology-related skincare conditions; and Cannabinoid and COX-2 inhibitor Conjugation. The ENVB YTD return is shown above.
The YTD Return on the ENVB YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ENVB YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ENVB YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|